Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression

Thromb Res. 2022 May:213:170-172. doi: 10.1016/j.thromres.2022.03.021. Epub 2022 Mar 31.

Authors

Francesco Paciullo¹, Eleonora Petito¹, Emanuela Falcinelli¹, Paolo Gresele², Stefania Momi¹

Affiliations

¹ Department of Medicine and Surgery, Division of Internal and Cardiovascular Medicine, University of Perugia, Italy.
² Department of Medicine and Surgery, Division of Internal and Cardiovascular Medicine, University of Perugia, Italy. Electronic address: paolo.gresele@unipg.it.

PMID: 35385821
DOI: 10.1016/j.thromres.2022.03.021

No abstract available

Keywords: Alirocumab; FVIII; LDLR; LRP1; Statins.

Publication types

Letter

MeSH terms

Anticholesteremic Agents* / pharmacology
Factor VIII* / metabolism
Hemostasis
Humans
Low Density Lipoprotein Receptor-Related Protein-1* / metabolism
PCSK9 Inhibitors* / pharmacology
Proprotein Convertase 9* / metabolism
Receptors, LDL / metabolism

Substances

Anticholesteremic Agents
LRP1 protein, human
Low Density Lipoprotein Receptor-Related Protein-1
PCSK9 Inhibitors
Receptors, LDL
F8 protein, human
Factor VIII
PCSK9 protein, human
Proprotein Convertase 9